Justin Cooper

WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of flare through 52 weeks compared with placebo, according to data presented at ACR Convergence 2024.

WASHINGTON — Herpes zoster vaccination is effective in patients with systemic lupus erythematosus and multiple sclerosis, without increasing the risk for severe lupus flares, according to data presented at ACR Convergence 2024.

WASHINGTON — A model predicting the development of systemic lupus erythematosus, based on genetic, lifestyle and environmental factors, was successfully

WASHINGTON — Dactylitis, psoriasis and other non-musculoskeletal manifestations of psoriatic arthritis can be accurately monitored through patient self-reporting, according to data presented at ACR Convergence 2024.

WASHINGTON — Different stages of gout treatment may call for different serum urate targets, with certain levels being better for dissolving or

WASHINGTON — Exposure to specific pesticides, including DDT, demonstrates “strong and significant” risks for rheumatoid arthritis among the female

WASHINGTON — Although even low-dose prednisone significantly increases the risk for fracture in systemic lupus erythematosus, there is no increased

WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less

WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including

WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or hip replacement over several years, according to a study presented at ACR Convergence 2024.